English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
हिन्दी
日本語
Amgen
AMGN,
has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.
Wezlana was approved as a biosimilar to and interchangeable with Stelara for treating adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease and moderate to severely active ulcerative colitis.
The treatment is also approved for treating patients 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis.
A biosimilar is a treatment that has no clinically meaningful difference from another treatment already approved by the FDA.
Read the full article here